The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens.

Resistance is an emerging problem in human medicine and the effects of resistance are being noted on an ever-increasing scale. Whether it is treatment of nosocomial bacteremia in New York City or community-acquired dysentery in Central Africa, multiresistant organisms are diminishing our ability to control the spread of infectious diseases. Clearly, the rate at which resistant organisms develop is not solely a function of the use of antimicrobials in humans, but is also highly influenced by the use of these agents in veterinary medicine, animal husbandry, agriculture, and aquaculture, as has been emphasized at recent meetings sponsored by organizations such as Rockefeller University and the American Society for Microbiology, and in the report on bacterial resistance recently issued by the US Office of Technology Assessment. We have entered an era where both physicians and patients must take on the responsibility to use antimicrobials wisely and judiciously. Just as in the days at the turn of the century when the public was an integral part of establishing quarantines for infectious diseases, now again the public's cooperation must be sought for this latest threat to public health. The multiresistant organisms of the 1990s are a grim warning of the possibility of the postantibiotic era.

[1]  O. Lyytikäinen,et al.  Outbreak caused by two multi-resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. , 1995, The Journal of hospital infection.

[2]  M. Cetron,et al.  The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. , 1995, The New England journal of medicine.

[3]  F. Tenover,et al.  Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci , 1995, Journal of clinical microbiology.

[4]  G. Jacoby,et al.  A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.

[5]  R. Wenzel,et al.  Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  R. Gonzales,et al.  What will it take to stop physicians from prescribing antibiotics in acute bronchitis? , 1995, The Lancet.

[7]  M. Gilchrist Recommendations for Preventing the Spread of Vancomycin Resistance , 1995, Infection Control & Hospital Epidemiology.

[8]  J. Hughes,et al.  Trends in antimicrobial drug prescribing among office-based physicians in the United States. , 1995, JAMA.

[9]  R. Gaynes,et al.  Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. , 1994, The Journal of infectious diseases.

[10]  J. Govan,et al.  Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis. , 1994, The Journal of antimicrobial chemotherapy.

[11]  P. Courvalin,et al.  Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens , 1994, Antimicrobial Agents and Chemotherapy.

[12]  M. Weinstein,et al.  Development of a standardized screening method for detection of vancomycin-resistant enterococci , 1994, Journal of clinical microbiology.

[13]  G. Wormser,et al.  Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit , 1994, Antimicrobial Agents and Chemotherapy.

[14]  A. Tomasz,et al.  Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop. , 1994, The New England journal of medicine.

[15]  J. Travis,et al.  Reviving the antibiotic miracle? , 1994, Science.

[16]  J M Hughes,et al.  Infectious disease surveillance: a crumbling foundation. , 1994, Science.

[17]  J Davies,et al.  Inactivation of antibiotics and the dissemination of resistance genes. , 1994, Science.

[18]  R. Gaynes,et al.  Addressing emerging infectious disease threats; a prevention strategy for the United States : executive summary , 1994 .

[19]  L. Sutton,et al.  Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases , 1994, Journal of clinical microbiology.

[20]  K S Meyer,et al.  Nosocomial Outbreak of Klebsiella Infection Resistant to Late-Generation Cephalosporins , 1993, Annals of Internal Medicine.

[21]  M. Arthur,et al.  Genetics and mechanisms of glycopeptide resistance in enterococci , 1993, Antimicrobial Agents and Chemotherapy.

[22]  K. Singh,et al.  Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  A. Telenti,et al.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.

[24]  Robert O. Walton,et al.  The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. , 1992, The Journal of infectious diseases.

[25]  H. Neu,et al.  The Crisis in Antibiotic Resistance , 1992, Science.

[26]  Mitchell L. Cohen Epidemiology of Drug Resistance: Implications for a Post—Antimicrobial Era , 1992, Science.

[27]  F. Tenover,et al.  Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. , 1992, The Pediatric infectious disease journal.

[28]  W. Noble,et al.  Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. , 1992, FEMS microbiology letters.

[29]  A. Podbielski,et al.  Identical genes confer high-level resistance to gentamicin upon Enterococcus faecalis, Enterococcus faecium, and Streptococcus agalactiae , 1992, Antimicrobial Agents and Chemotherapy.

[30]  F. Tenover Novel and emerging mechanisms of antimicrobial resistance in nosocomial pathogens. , 1991, The American journal of medicine.

[31]  G. Jacoby,et al.  More extended-spectrum beta-lactamases , 1991, Antimicrobial Agents and Chemotherapy.

[32]  B. Murray New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. , 1991, The Journal of infectious diseases.

[33]  C. Carlier,et al.  Gene homogeneity for aminoglycoside-modifying enzymes in gram-positive cocci , 1990, Antimicrobial Agents and Chemotherapy.

[34]  G. Papanicolaou,et al.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility , 1990, Antimicrobial Agents and Chemotherapy.

[35]  K. Klugman Pneumococcal resistance to antibiotics , 1990, Clinical Microbiology Reviews.

[36]  H. Neu Quinolones. An overview. , 1990, Diagnostic microbiology and infectious disease.

[37]  T. Gootz Discovery and development of new antimicrobial agents , 1990, Clinical Microbiology Reviews.

[38]  J. Mcgowan,et al.  Antimicrobial susceptibility in gram-negative bacteremia: are nosocomial isolates really more resistant? , 1989, Antimicrobial Agents and Chemotherapy.

[39]  H. Nikaido Outer membrane barrier as a mechanism of antimicrobial resistance , 1989, Antimicrobial Agents and Chemotherapy.

[40]  G. Jacoby,et al.  Extended-spectrum beta-lactamases , 1989, Antimicrobial Agents and Chemotherapy.

[41]  C. Hackbarth,et al.  Methicillin-resistant staphylococci: genetics and mechanisms of resistance , 1989, Antimicrobial Agents and Chemotherapy.

[42]  W. Sougakoff,et al.  Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type penicillinase genes. , 1988, Reviews of infectious diseases.

[43]  P. Trieu-Cuot,et al.  In vivo transfer of genetic information between gram‐positive and gram‐negative bacteria. , 1985, The EMBO journal.

[44]  H. Neu The new beta-lactamase-stable cephalosporins. , 1982, Annals of internal medicine.

[45]  Ian Phillips,et al.  &bgr;-LACTAMASE-PRODUCING, PENICILLIN-RESISTANT GONOCOCCUS , 1976, The Lancet.

[46]  S. Falkow,et al.  Plasmid-linked ampicillin resistance in haempohilus influenza type b , 1975, Infection and immunity.

[47]  D. Smith,et al.  Recovery of resistance factors from a drug-free community. , 1969, Lancet.

[48]  T. Akiba,et al.  On the mechanism of the development of multiple-drug-resistant clones of Shigella. , 1960, Japanese journal of microbiology.

[49]  W. M. Kirby EXTRACTION OF A HIGHLY POTENT PENICILLIN INACTIVATOR FROM PENICILLIN RESISTANT STAPHYLOCOCCI , 1944, Science.

[50]  E. Abraham,et al.  An Enzyme from Bacteria able to Destroy Penicillin , 1940, Nature.

[51]  A. D. Gardner Morphological Effects of Penicillin on Bacteria , 1940, Nature.

[52]  C. Infante-Rivard,et al.  Otitis media in children: frequency, risk factors, and research avenues. , 1993, Epidemiologic reviews.

[53]  Joshua Lederberg,et al.  Emerging Infections: Microbial Threats to Health in the United States , 1992 .

[54]  B. Murray,et al.  In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin. , 1986, The Journal of clinical investigation.

[55]  D. Clewell,et al.  Conjugative transposons and the dissemination of antibiotic resistance in streptococci. , 1986, Annual review of microbiology.